🌟 Highlights
| 🧬 Key Focus | 💡 Details |
|---|---|
| 🚀 Innovation | Developing two proprietary drug candidates targeting advanced cancer and cancer stem cells. |
| 🔐 IP Protection | Drug candidates are protected by granted patents in the US and China. |
| 🌍 Market Size | Global precision oncology market estimated at $115.32M in 2024. |
| 👨⚕️ Leadership | Led by a highly experienced team in oncology and drug development. |
💡 The Idea
🔬 Problem
Cancer remains one of the top global killers, with nearly 20 million new diagnoses in 2022. A key challenge lies in the failure of current therapies to effectively target tumour sites, reducing treatment success and leading to increased resistance.
🧪 Solution
Our proprietary proteins, S4 and AB1, are designed to treat cancers with Mastermind/Notch or P53 mutations, present in most patients. These novel human therapeutic proteins offer distinct advantages over current and in-development treatments.
💼 Business Model
Our strategy includes forming strategic partnerships and exploring licensing opportunities for our drug candidates S4 and AB1 with pharmaceutical companies.
👥 Team
| 🧑🔬 Name | 🎓 Role | |
|---|---|---|
| Agamemnon Epenetos | Director / Co-Founder / Chairman & CEO | |
| Mahendra Deonarain | Co-Founder & Scientific/Technical Consultant (Advisor) | |
| Christina Kousparou | Associate Professor of Immunology (Board Member) | |
| Carmel Reilly | Biotech Founder and CEO (Advisor) |
